Ascendis Pharma announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application for TransCon CNP. The treatment, aimed at children with achondroplasia, has been granted a Prescription Drug User Fee Act (PDUFA) goal date of November 30, 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.